ELISA/assay

Coagulation Factor VIII (F8) ELISA Kit

MBS2019452

48-Strip-Wells

550 USD

ELISA Kit

Coagulation Factor VIII (F8) ELISA Kit

Coagulation Factor VIII (F8)

FVIII; AHF; HEMA; F8B; F8C; Antihemophilic Globulin; Hemophilia A; Anti-Hemophilic Factor A; FVIII Procoagulant Component; F8 Protein

coagulation factor VIII isoform 1; Coagulation factor VIII; coagulation factor VIII; coagulation factor VIII; Procoagulant component

F8

F8; F8; Cf8; Cf-8; FVIII; Cf8; F8c

FA8_MOUSE

Mouse

2319

This assay has high sensitivity and excellent specificity for detection of Coagulation Factor VIII (F8). No significant cross-reactivity or interference between Coagulation Factor VIII (F8) and analogues was observed.

For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 degree C upon receipt while the others should be at 4 degree C. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant pack, and reseal along entire edge of zip-seal. The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Samples: Plasma. Assay Type: Sandwich. Detection Range: 0.625-40ng/mL. Sensitivity: Typically less than 0.275ng/mL.

Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Coagulation Factor VIII (F8) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Coagulation Factor VIII (F8) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 . Intra-Assay: CV<10% . Inter-Assay: CV<12% . Assay Procedure Summary: 1. Prepare all reagents, samples and standards;. 2. Add 100uL standard or sample to each well. Incubate 2 hours at 37 degree C;. 3. Aspirate and add 100uL prepared Detection Reagent A. Incubate 1 hour at 37 degree C;. 4. Aspirate and wash 3 times;. 5. Add 100uL prepared Detection Reagent B. Incubate 30 minutes at 37 degree C;. 6. Aspirate and wash 5 times;. 7. Add 90uL Substrate Solution. Incubate 15-25 minutes at 37 degree C;. 8. Add 50uL Stop Solution. Read at 450nm immediately.

Principle of the Assay: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Coagulation Factor VIII (F8). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Coagulation Factor VIII (F8). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Coagulation Factor VIII (F8), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm 10nm. The concentration of Coagulation Factor VIII (F8) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

238624180

NP_032003.2

NM_007977.2

Q06194

266,196 Da

Blood Clotting Cascade Pathway (198388); Common Pathway (1110057); Complement And Coagulation Cascades Pathway (198335); Complement And Coagulation Cascades Pathway (83270); Complement And Coagulation Cascades Pathway (484); Formation Of Fibrin Clot (Clotting Cascade) Pathway (1110054); Hemostasis Pathway (1110026); Intrinsic Pathway (1110056); Platelet Activation, Signaling And Aggregation Pathway (1110036); Platelet Degranulation Pathway (1110053)

F8: Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. Defects in F8 are the cause of hemophilia A (HEMA). A disorder of blood coagulation characterized by a permanent tendency to hemorrhage. About 50% of patients have severe hemophilia resulting in frequent spontaneous bleeding into joints, muscles and internal organs. Less severe forms are characterized by bleeding after trauma or surgery. Of particular interest for the understanding of the function of F8 is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8 in their plasma (at least 30% of normal), but the protein is non- functional; i.e. the F8 activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein. Belongs to the multicopper oxidase family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Secreted; Secreted, signal peptide. Cellular Component: extracellular space; extracellular region. Molecular Function: copper ion binding; serine-type endopeptidase activity; metal ion binding; oxidoreductase activity. Biological Process: platelet activation; hemostasis; acute-phase response; blood coagulation; proteolysis; blood coagulation, intrinsic pathway

48-Strip-Wells

550 USD

96-Strip-Wells

750

5x96-Strip-Wells

2910

10x96-Strip-Wells

5220